2025
Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi
Wenger C, Asare E, Kwon J, Li X, Mwinjiwa E, Chinkhumba J, Jere K, Hungerford D, Cunliffe N, Paltiel A, Pitzer V. Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi. PLOS Global Public Health 2025, 5: e0004341. PMID: 40209158, PMCID: PMC11984971, DOI: 10.1371/journal.pgph.0004341.Peer-Reviewed Original ResearchDose of RotarixNeonatal vaccinationThird doseDisability-adjusted life yearsRotavirus vaccination strategiesVaccination strategiesVaccination scheduleRV3-BB vaccineRotavirus vaccine scheduleModerate-to-severeCurrent rotavirus vaccinesProbabilistic sensitivity analysesRV3-BBPrevent rotavirusRotavirus casesRotavirus vaccineWTP thresholdAlternate infantsVaccine impactSevere diarrheaWeeks of ageRotarixVaccine effectivenessCost-effectiveness analysisCost-effective
2019
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The Lancet Infectious Diseases 2019, 19: 728-739. PMID: 31130329, PMCID: PMC6595249, DOI: 10.1016/s1473-3099(18)30804-1.Peer-Reviewed Original ResearchConceptsGross domestic productWTP valuesCountry's gross domestic productOptimal strategyCountry-specific willingnessAverage net benefitHealth economic evaluationsGAVI-eligible countriesTyphoid ViPay valueDomestic productVaccine priceWTP thresholdEconomic evaluationVaccine-related costsNet benefitMiddle-income countriesGavi supportVaccine AllianceRoutine immunisationHospital admissionCountriesTCV introductionDALYsTransmission dynamic model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply